Shares of clinical-stage biotechnology company, CohBar, Inc. (CWBR) rose 160% on Monday morning trade, on news of CohBar and cancer vaccine developer, Morphogenesis' definitive agreement for an all-stock merger under the combined company name of "TuHURA Biosciences, Inc."
CWBR is currently trading at $4.03, up 160% or $2.48 per share, on Nasdaq. It has traded between $1.43 and $7.50 in the past 52-week period.
TuHURA Bioscience Inc. will focus on advancing Morphogenesis' two technologies that seek to overcome the major obstacles that limit the effectiveness of current immunotherapies in treating cancer.
For comments and feedback contact: editorial@rttnews.com
Business News